» Articles » PMID: 2681418

Characterization of IL-6 Receptor Expression by Monoclonal and Polyclonal Antibodies

Overview
Journal J Immunol
Date 1989 Nov 1
PMID 2681418
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

mAb and polyclonal antibodies against human IL-6R were prepared by using a murine transfectant cell line expressing the human IL-6R and a synthetic oligopeptide made on the basis of the deduced amino acid sequence as immunogens. Immunoprecipitation of radiolabeled IL-6R with these antibodies showed that the Mr of a mature IL-6R was 80 kDa and its value was reduced to 50K after treatment with O- and N-glycanase and neuraminidase, indicating that IL-6R is a glycoprotein. Two mAb recognizing different epitopes were prepared. One, PM1 inhibited the binding of 125I-IL-6 to the receptor and blocked the IL-6-dependent growth of a T lymphoma line, KT3. PM1 could not bind to IL-6R when it was saturated with IL-6, indicating that this antibody recognizes the IL-6 binding or the adjacent site on IL-6R. The other, MT18 was not inhibited by IL-6 for its recognition of IL-6R, therefore, this could be used for cytofluorometric staining of normal cells. Nonstimulated B cells expressed undetectable amount of IL-6R regardless of the expression of surface IgD. However, after the stimulation with PWM, IL-6R was observed on IgD- B cells with a relatively large size, but subtly on IgD- small B cells and not on IgD+ B cells, fitting the function of IL-6 which acts on activated B cells to induce Ig production. In contrast, IL-6R was detected on non-stimulated CD4+/CD8- and CD4-/CD8+ T cells. The level of IL-6R on both T cell subpopulations was not significantly changed after stimulation with phytohemagglutinin.

Citing Articles

Small protein blockers of human IL-6 receptor alpha inhibit proliferation and migration of cancer cells.

Groza Y, Lacina L, Kuchar M, Raskova Kafkova L, Zachova K, Janouskova O Cell Commun Signal. 2024; 22(1):261.

PMID: 38715108 PMC: 11075285. DOI: 10.1186/s12964-024-01630-w.


Interleukin-6 in Traumatic Brain Injury: A Janus-Faced Player in Damage and Repair.

Ciryam P, Gerzanich V, Simard J J Neurotrauma. 2023; 40(21-22):2249-2269.

PMID: 37166354 PMC: 10649197. DOI: 10.1089/neu.2023.0135.


COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire.

Seddiki N, French M Front Immunol. 2021; 12:649567.

PMID: 33841434 PMC: 8024517. DOI: 10.3389/fimmu.2021.649567.


Urban particulate matter stimulation of human dendritic cells enhances priming of naive CD8 T lymphocytes.

Pfeffer P, Ho T, Mann E, Kelly F, Sehlstedt M, Pourazar J Immunology. 2017; 153(4):502-512.

PMID: 29044495 PMC: 5838419. DOI: 10.1111/imm.12852.


Interleukin-6 (IL-6) mediated the increased contraction of distal colon in streptozotocin-induced diabetes in rats via IL-6 receptor pathway.

Chang X, Qin Y, Jin Z, Xi T, Yang X, Lu Z Int J Clin Exp Pathol. 2015; 8(5):4514-24.

PMID: 26191141 PMC: 4503013.